Immunogenicity of a liquid hexavalent DTaP-IPV-HB-PRP∼T vaccine after primary and booster vaccination of term and preterm infants born to women vaccinated with Tdap during pregnancy.

BACKGROUND: Vaccination during pregnancy with tetanus, diphtheria, acellular pertussis (aP) (Tdap) antigens is important for early protection of newborn infants against pertussis, particularly for preterm infants. This study evaluated the effect of Tdap vaccination during pregnancy on the immunogenicity of a diphtheria (D), tetanus (T), aP, inactivated poliovirus (IPV), hepatitis B (HB), and Haemophilus influenzae type b (PRP âˆ¼ T) vaccine in term and preterm populations. METHODS: A prospective, observational study (NCT02511327) recruited women and their infants based on delivery (term or preterm) and vaccination status (vaccinated with a Tdap vaccine [Boostrix™, GlaxoSmithKline] during pregnancy or not vaccinated in the last 5 years). All infants received licensed DTaP-IPV-HB-PRP âˆ¼ T (Hexyon™, Sanofi) (8, 12, 16 week primary series and booster at 13 months of age [preterm infants] or 15 months of age [term infants]). Immunogenicity was evaluated using validated assays. Data were pooled into term (N = 127) and preterm infants (N = 105), and infants of women who received a Tdap vaccine during pregnancy (N = 199) or not (N = 33). RESULTS: Before primary vaccination, antibody levels were higher for term than preterm infants for anti-D, anti-polio 1, 2, 3, anti-PT, anti-FHA, and anti-PRP, and similar for anti-HBs and anti-T. At this time, infants of Tdap-vaccinated women had higher anti-D, anti-T, anti-PT, anti-FHA, and anti-PRP antibody levels than infants of Tdap-unvaccinated women; anti-HBs and anti-polio antibody levels were similar in both groups. Post-primary, pre-booster, and post-booster, there were only small differences in seroprotection rates (anti-D, anti-T, anti-polio 1, 2, 3, anti-HBs, anti-PRP) and seroconversion rates (anti-PT, anti-FHA), except for anti-HBs ≥ 10 mIU/mL and anti-PRP ≥ 0.15 µg/mL post-primary vaccination (higher for term [98.31 % and 90.91 %, respectively] versus preterm infants [89.80 % and 79.41 %, respectively]). CONCLUSIONS: These data support the use of DTaP-IPV-HB-PRP âˆ¼ T vaccine for primary and booster vaccination in term and preterm born infants and in infants born to Tdap-vaccinated or Tdap-unvaccinated women.

Interchangeability of Hepatitis A boosters, Avaxim and Vaqta, in healthy adults following a primary dose of the combined typhoid/Hepatitis A vaccine Viatim.

This study investigated the suitability of Avaxim and Vaqta as Hepatitis A booster vaccines 6 months after priming with the combined Hepatitis A/typhoid vaccine, Viatim. One hundred and twenty adults were randomly assigned to one of the three groups. Group A (reference group) received Avaxim then Avaxim (n = 40), Group B received Viatim then Avaxim (n = 41) and Group C received Viatim then Vaqta (n = 39). One month after booster vaccination, anti-Hepatitis A virus (anti-HAV) antibodies geometric mean concentrations (GMC) of subjects primed with Viatim were non-inferior to the group primed and boosted with the monovalent Hepatitis A vaccine Avaxim. Anti-Salmonella typhi capsular polysaccharide virulence antigen (anti-Vi) GMCs in groups primed with Viatim were protective and all vaccines were well-tolerated. Therefore, Viatim may be used as a primary HAV vaccine with either Avaxim or Vaqta as Hepatitis A boosters and it will provide the same protection as two doses of Avaxim.

[Central nervous system demyelinating disease following hepatitis B vaccination with GenHevac B. Review of ten years of spontaneous notifications (1989-1998)]. / Pathologies démyélinisantes du système nerveux central rapportées après vaccination hépatite B par GenHevac B. Bilan de dix années de notifications spontanées (1989-1998).

OBJECTIVES: To describe and analyze spontaneous reports of central nervous system (CNS) demyelinating disease including multiple sclerosis, following vaccination with GenHevac B vaccine, from 1989 to December 31, 1998. METHODS: Descriptive analysis of adverse event reports in the vaccinated population, including the number of cases of CNS demyelinating disease, their frequencies, their dates of onset in relation to dates of report and their distribution according to age, sex and the number of injections. A Kaplan-Meier curve was used to analyze the time period between the last dose of vaccine and the onset of CNS demyelinating disease. RESULTS: Overall, 187 cases of CNS demyelinating disease were spontaneously reported, (0.54 reports per 100,000 doses of GenHevac B distributed). The average time period between the occurring date of onset of the disease and its subsequent report was 24 months. The average age of onset was 31.7 years old and 73% of cases were women. The time between the last dose of vaccine and the onset of disease was regularly distributed from 1 day to 5 years (median: 60 days). CONCLUSION: These results, together with available clinical, epidemiological data regarding multiple sclerosis, do not suggest a causal relationship between CNS demyelinating disease and vaccination with GenHevac B.